Aspire Biopharma Holdings, Inc. (ASBP)
NASDAQ: ASBP · Real-Time Price · USD
0.6001
-0.0399 (-6.23%)
Mar 31, 2025, 3:35 PM EDT - Market open
Company Description
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States.
The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management.
It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs.
The company was founded in 2021 and is based in Humacao, Puerto Rico.
Aspire Biopharma Holdings, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kraig Higginson |
Contact Details
Address: 194 Candelero Drive, Suite 223 Humacao, PR 00791 United States | |
| Phone | 415 592 7399 |
| Website | aspirebiolabs.com |
Stock Details
| Ticker Symbol | ASBP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001995528 |
| ISIN Number | KYG7207P1037 |
Key Executives
| Name | Position |
|---|---|
| Kraig T. Higginson | President, Chief Executive Officer and Chairman of Board |
| Ernest J. Scheidemann Jr. | Chief Financial Officer |
| Stephen E. Quesenberry | General Counsel, Corporate Secretary and Director |